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OBJECTIVE: The aim of this study was to establish the
epidemiological features of agitation and aggressiveness
in patients aged 65 years or older and living at home and
what the etiological factors might be, to begin a cost
analysis in the absence of published data. 
METHODS: Prevalence was estimated, first, in a random
sample of 3777 elderly subjects (the PAQUID cohort), us-
ing DSM-III criteria and psychologists’ reports, at differ-
ent timepoints; second, in the patients of a nationally rep-
resentative sample from 159 general practitioners, from
diagnoses based on behaviors and clinical scrutiny. A na-
tional retrospective study including 410 patients was con-
ducted to investigate the consequences of symptoms such
as somatic troubles, social disability and dependence. Dis-
ability was also evaluated in the PAQUID cohort with the
AGGIR scale used to identify patients eligible to a depen-
dence-specific benefit. Risk factors (age, gender, medical
variables, etc.) were examined.
RESULTS: In 1997, the prevalence of agitation and aggres-
siveness ranged between 0.19% and 0.34% of the French
population. Of concerned subjects, 55% presented two to
three somatic troubles, 97% a restriction of social life, and
85% a restriction of daily activities. Prevalence depended
positively on age. Men exhibited more symptoms than
women (p  0.0001). Agitation and aggressiveness were
mainly associated with dementia and psychiatric diseases,
but demented subjects showed more physical agitation (p 
0.02), social disability, and dependence (p  0.0001).
CONCLUSION: The economic impact of agitated and
aggressive behaviors of elderly individuals should be
great due to the high degree of associated disability, and
it will likely increase in the future.
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OBJECTIVE: This study was designed to estimate the
cost incurred by French Social Security due to agitated
and aggressive behaviors of patients aged 65 years or
older, living at home.
METHODS: Economic appraisal was performed on a
representative sample of 410 patients included by 212
general practitioners in a national specific retrospective
survey. The bottom-up approach to calculating cost of
those psychotic symptoms for total population was based
on our preliminary estimation of their prevalence. The
whole direct medical costs were taken into account so as
to discover the medical costs of dependence associated
with behavior troubles. The main determinants of costs
were examined through the various profiles of patients
we pointed out.
RESULTS: In 1997, the average cost to the French Social
Security of an agitated and aggressive old patient dwell-
ing in the community was estimated at 23,513  1,665
FF. It varied with the age of patients, from 18,392 
2,642 FF in the 65–78 year age bracket to 21,920 
3,447 FF in the 88–99 year bracket, with a peak in the
group of patients aged 79–87 (29,724  2,675 FF) (p 
0.01). The average cost of demented patients (27,791 
2,239 FF) appeared to be significantly higher than that of
nondemented (18,410  2,445 FF) (p  0.005). Health-
care services at home for dependent patients were the
most costly category of service.
CONCLUSION: Our results highlight the economic in-
terest of better controlling behavior disorders with special
emphasis on demented patients in order to prevent them
from becoming dependent.
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University of Toronto, Toronto, Canada
BACKGROUND: Schizophrenia imposes a heavy eco-
nomic burden due to its early onset, high morbidity and
mortality, chronicity, and limited response to traditional
pharmacotherapy. Newer antipsychotics such as risperi-
done improve both negative and positive symptoms, and
impact on economic and quality-of-life measures. How-
ever, the acquisition cost of risperidone is higher than
that of traditional agents. An economic evaluation was
performed to compare risperidone with oral haloperidol,
depot haloperidol, and fluphenazine, to assess relative
differences in costs and consequences. 
METHODS: A cost-utility analysis was performed using a
decision analytic model with the perspective of the Ontario
government (Canada). Probabilities including success rates,
dropouts due to adverse events, and EPS were determined
from a systematic review of the literature. Costs were ob-
tained from the provincial formulary and fee schedules,
standard lists for community resources, and hospital case
costing. Utilities were measured in 25 stable patients with
schizophrenia, using the Standard Gamble technique, and
combined with the clinical outcomes into a measure of
quality-adjusted life-years (QALYs).
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RESULTS: Risperidone dominated all comparators, hav-
ing the highest clinical success rate (67%), greatest num-
ber of QALYs (0.89), and lowest expected costs (CDN
$69,885) over a 1-year period. Fluphenazine had the
highest expected cost (CDN $82,264) and lowest number
of QALYs (0.85). Both oral and depot haloperidol were
associated with higher total expected costs and lower
number of QALYs than risperidone. 
CONCLUSIONS: The use of risperidone in place of halo-
peridol in Canada would be associated with annual sav-
ings of CDN $832 million in hospital expenditures, CDN
$113 million in incremental drug expenditures, and CDN
$180 million in annual incremental community care ex-
penses. Prospective validation of our findings, as well as
comparisons with the US and Europe, may be warranted.
ECONOMIC AND OUTCOMES STUDY RESULTS 
FOR DIABETES AND INFECTIOUS DISEASE
D1
SELF-MONITORING OF BLOOD GLUCOSE IN 
DIABETES: IS IT WORTH IT?
Evans JMM, Boyle DIR, Davey P, Morris AD
The DARTS/MEMO Collaboration, Dundee University, 
Dundee, Scotland
OBJECTIVES: To investigate patterns and costs of self-
monitoring of blood glucose, and its effect on glycemic
control, among insulin-using diabetic patients in Tayside,
Scotland.
METHODS: The population-based DARTS diabetes da-
tabase was used to identify all insulin-using patients diag-
nosed with type 1 or type 2 diabetes prior to 1993. The
numbers of glucose-monitoring test strips dispensed in
1993–1995 were determined from the MEMO-dispensed
prescribing database, and average costs per patient calcu-
lated. The effect of self-monitoring on glycemic control
was investigated in a linear regression model (with
HbA1c as the outcome variable). Independent variables
were numbers of strips dispensed in the 6 months prior to
the HbA1c reading, age, sex, and deprivation.
RESULTS: Among 807 patients with type 1 diabetes,
15% obtained no test strips, 20% obtained enough strips
to test glucose daily, and 1% for four times daily. The
corresponding figures for the 1,240 insulin-using patients
with type 2 diabetes were 30% (no strips) and 12%
(daily tests). Age and deprivation influenced strip uptake.
Average costs/patient/year were £64.40 for type 1 diabe-
tes and £44.80 for type 2 diabetes, compared with £409
for self-monitoring four times daily (recommended in the
DCCT). For 258 patients with type 1 diabetes who had
HbA1c values recorded, there was an association be-
tween strip uptake and glycemic control (p  0.001),
with an estimated decrease in HbA1c of 0.7% for every
180 test strips dispensed. There was no such association
for 529 insulin-using patients with type 2 diabetes. 
CONCLUSIONS: Self-monitoring of blood glucose im-
proves glycemic control in type 1 diabetes, but a minority
of patients self-monitor regularly. Costs are moderate
compared with other costs of diabetes care.
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PATIENT-HELD INSTRUMENTS FOR 
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USE: EXPERIENCE IN PATIENTS WITH 
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BACKGROUND: Patients with diabetic foot ulcers re-
quire long-term management by community-based health-
care providers. To determine the amount of health re-
sources used by patients with foot ulcers, we constructed a
patient-held booklet for recording ambulatory care re-
source use alongside a multinational trial (contacts, dress-
ings, topical medications).
OBJECTIVE: To evaluate the acceptability and com-
pleteness of the booklet.
METHOD: Thirty-seven patients in five study centers (in
the UK and Spain) were asked to use the booklet for 4
weeks. Local center coordinators interviewed patients
and clinicians and transferred data from the booklet onto
the trial economic case report form (CRF).
RESULTS: Thirty-four (92%) patients returned the
booklet to local coordinators; two had been admitted to
hospital; one was lost to follow-up. Of patients, 91%
found the booklet easy to use, and 94% remembered to
carry the booklet with them most of the time. Thirty
(91%) participating clinicians reported that the booklet
was easy to use. Comments about the booklet included:
(a) size of the text: too small; (b) volume: too bulky; (c)
look-up list of dressings and topical medications: difficult
to use. Of 277 contacts with clinicians reported in the
booklets, 256 (92%) were transferred to the CRF. Partic-
ipants recorded 1,004 dressing changes and 1,065 appli-
cations of topical medications in the booklets, 95% and
98% of which were transferred to the CRF. The number
of contacts recorded in the booklet was found to be con-
sistent with an independent report from participating
clinicians in 18 out of 19 cases for which information
was provided.
CONCLUSION: The patient-held booklet is an accept-
able data collection instrument, which with minor modi-
fications is suitable for use in ambulatory care settings.
